A multi-center, open-label, randomized dose expansion study of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Kelly, William Kevin [1 ]
Hussain, Arif [2 ]
Saraiya, iren [3 ]
Thanigaimani, Pradeep [4 ]
Sun, Furong
Seebach, Frank A.
Lawy, Israel
Sandigursky, Sabina
Miller, Elizabeth
机构：
[1] Thomas Jefferson Univ, Philadelphia, PA USA
[2] Univ Maryland, Med Ctr, Baltimore, MD USA
[3] Rutgers State Universityof New Jersey, Canc Inst New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ USA
[4] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 6_SUPPL期
关键词：
283-2494-5577-2829; 613-225-325; 261-566-9263; 283-224-11611-3642-3956; 283-197-6219; 613-225-2782; 261-492-3532-9726; 6; 5; 4; 3; 2; 60; 1; 38092-22583;
D O I：
10.1200/JCO.2023.41.6_suppl.TPS282
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS282
引用
收藏
页码：TPS282 / TPS282
页数：1
相关论文
共 50 条
  • [21] First prospective, open-label, phase 2 study of sipuleucel-T (sip-T) in European men with metastatic, castration-resistant prostate cancer (mCRPC).
    De Santis, Maria
    Mulders, Peter
    Fizazi, Karim
    Gray, Todd E.
    McCoy, Candice
    Stubbs, Andrew
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [22] An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (mCRPC; CheckMate 9KD).
    Fizazi, Karim
    Drake, Charles G.
    Shaffer, David R.
    Pachynski, Russell
    Saad, Fred
    Ciprotti, Marika
    Kong, George
    Ryan, Charles J.
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] ProSTAR: A phase lb/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Taplin, Mary-Ellen
    Hussain, Arif
    Shah, Satish
    Shore, Neal D.
    Agrawal, Manish
    Clark, William
    Edenfield, William Jeffery
    Nordquist, Luke T.
    Sartor, Oliver A.
    Butrynski, James E.
    Chatta, Gurkamal S.
    Fleming, Mark T.
    Oh, William K.
    Bradley, Bill
    Piel, Jessica
    Nash, David
    Colak, Gozde
    Li, Jian
    Lebedinsky, Claudia
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [24] Phase 2 multi-center study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
    Morschhauser, Franck
    Salles, Gilles A.
    Le Gouill, Steven
    Radford, John A.
    McKay, Pamela
    Cartron, Guillaume
    Pimentel, Patricia J.
    Roche, Maria
    Blakemore, Stephen J.
    McDonald, Alice
    Warholic, Natalie
    Knight, Shelley
    Ho, Peter T. C.
    Ribrag, Vincent
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD) a multicentre, open-label, phase 2 trial
    Smith, Matthew R.
    Scher, Howard, I
    Sandhu, Shahneen
    Efstathiou, Eleni
    Lara, Primo N.
    Yu, Evan Y.
    George, Daniel J.
    Chi, Kim N.
    Saad, Fred
    Stahl, Olof
    Olmos, David
    Danila, Daniel C.
    Mason, Gary E.
    Espina, Byron M.
    Zhao, Xin
    Urtishak, Karen A.
    Francis, Peter
    Lopez-Gitlitz, Angela
    Fizazi, Karim
    LANCET ONCOLOGY, 2022, 23 (03): : 362 - 373
  • [26] Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
    Fizazi, Karim
    Massard, Christophe
    Bono, Petri
    Jones, Robert
    Kataja, Vesa
    James, Nicholas
    Garcia, Jorge A.
    Protheroe, Andrew
    Tammela, Teuvo L.
    Elliott, Tony
    Mattila, Leena
    Aspegren, John
    Vuorela, Annamari
    Langmuir, Peter
    Mustonen, Mika
    LANCET ONCOLOGY, 2014, 15 (09): : 975 - 985
  • [27] Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
    Teply, Benjamin A.
    Wang, Hao
    Luber, Brandon
    Sullivan, Rana
    Rifkind, Irina
    Bruns, Ashley
    Spitz, Avery
    DeCarli, Morgan
    Sinibaldi, Victoria
    Pratz, Caroline F.
    Lu, Changxue
    Silberstein, John L.
    Luo, Jun
    Schweizer, Michael T.
    Drake, Charles G.
    Carducci, Michael A.
    Paller, Channing J.
    Antonarakis, Emmanuel S.
    Eisenberger, Mario A.
    Denmeade, Samuel R.
    LANCET ONCOLOGY, 2018, 19 (01): : 76 - 86
  • [28] A Phase II, Randomized, Open-Label, Multi-arm Study of TAS-115 for Castration-Resistant Prostate Cancer Patients With Bone Metastases
    Matsubara, Nobuaki
    Uemura, Hirotsugu
    Nagamori, Satoshi
    Suzuki, Hiroyoshi
    Uemura, Hiroji
    Kimura, Go
    CLINICAL GENITOURINARY CANCER, 2021, 19 (06) : 491 - 500
  • [29] A phase 3, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Azad, Arun
    Agarwal, Neeraj
    Carles, Joan
    Chowdhury, Simon
    McGregor, Bradley
    Merseburger, Axel
    Oudard, Stephane
    Saad, Fred
    Soares, Andrey
    Kerloeguen, Yannick
    Benzaghou, Fawzi
    Panneerselvam, Ashok
    Mohamed, Nehal
    Wang, Fong
    Pal, Sumanta
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 201 - 201
  • [30] Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer
    Corcoran, N. M.
    Hovens, C. M.
    Michael, M.
    Rosenthal, M. A.
    Costello, A. J.
    BRITISH JOURNAL OF CANCER, 2010, 103 (04) : 462 - 468
12345